We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DS-1062

News List

AstraZeneca, Daiichi Sankyo Announce Collaboration for New Antibody Drug Conjugate americanpharmaceuticalreview
August 04, 2020
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential ...
Daiichi Sankyo, AstraZeneca Enter New $6B Global ADC Alliance contractpharma
August 03, 2020
To jointly develop and commercialize DS-1062, a TROP2 directed DXd antibody drug conjugate in Phase I for non-small cell lung cancer and breast cancer.
AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo pharmaceutical-technology
July 28, 2020
AstraZeneca has signed a new agreement to develop and commercialise Japanese company Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), DS-1062, globally for various tumour types.
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer pharmaceutical-business-review
July 06, 2020
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).